Drug Trial Radar · NCT06998524
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Jun 27, 2025
Primary completion
Oct 6, 2027
Study completion Sep 6, 2029
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab prophylaxis in participants aged 1 month and above, who have been diagnosed with Type 3 von Willebrand disease (VWD). Participants on prior standard of care (SOC) on-demand therapy will be assessed via a randomized comparison (Arm A - emicizumab prophylaxis and Arm B - continuation of SOC on-demand therapy), while participants on prior SOC prophylactic therapy (Arm C - emicizumab prophylaxis) will be assessed via intra-participant analysis with data obtained from the preceding non-interventional study (NIS), WP45335 (NCT06883240).
Conditions
- Von Willebrand Disease, Type 3
Interventions
EmicizumabDrug
Participants will receive emicizumab 3 milligrams per kilogram (mg/kg) subcutaneous (SC) injections every week (QW) for the first 4 weeks as loading doses, followed by maintenance doses of emicizumab 3 mg/kg SC once every 2 weeks (Q2W). During the extension period, participants may remain on maintenance dose of emicizumab 3 mg/kg Q2W, or change their emicizumab maintenance regimen to 1.5 mg/kg once every week (QW) or 6 mg/kg once every 4 weeks (Q4W), if they prefer and if agreed by the investigators.
von Willebrand Factor (VWF) ConcentratesDrug
Used according to local labeling or local treatment guidelines.
Factor VIII (FVIII) ConcentratesDrug
Used according to local labeling or local treatment guidelines.
von Willebrand Factor (VWF) and Factor VIII (FVIII) ConcentratesDrug
Used according to local labeling or local treatment guidelines.
Bypassing AgentsDrug
Used according to local labeling or local treatment guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Bleed Rate (ABR) for Treated Bleeds in the Randomized ArmsTime frame: From Baseline to at least 24 weeks
Locations
30 sites in 14 countries. Site status is shown where the registry gives one.
UC Davis
Sacramento, California · Recruiting
University of Florida
Gainesville, Florida · Recruiting
University of Kentucky Children's Hospital
Lexington, Kentucky · Recruiting
University of Minnesota Medical Center
Minneapolis, Minnesota · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Virginia Commonwealth University
Richmond, Virginia · Recruiting
UZ Leuven Gasthuisberg
Leuven, Belgium · Recruiting
The Hospital for Sick Children
Toronto, Ontario, Canada · Recruiting
McGill University Health Center
Montreal, Quebec, Canada · Recruiting
IPS SURA Industriales Medellín
Medellín, Colombia · Recruiting
Hopital Claude Huriez - CHU Lille
Lille, France · Recruiting
Groupe Hospitalier Necker Enfants Malades
Paris, France · Recruiting
Universitätsklinikum Bonn
Bonn, Germany · Recruiting
Gerinnungszentrum Rhein-Ruhr;Gerinnungsambulanz
Duisburg, Germany · Recruiting
Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin
Frankfurt/M., Germany · Recruiting
Universita' Degli Studi La Sapienza-Ist.Di Ematologia
Rome, Lazio, Italy · Recruiting
IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Lombardy, Italy · Recruiting
AOU Careggi
Florence, Tuscany, Italy · Recruiting
Kurume University Hospital
Fukuoka, Japan · Recruiting
Nagoya University Hospital
Nagoya, Japan · Recruiting
Erasmus MC
Rotterdam, Netherlands · Recruiting
Instytut Hematologii i Transfuzjologii
Warsaw, Poland · Recruiting
Charlotte Maxeke Johannesburg Academic Hospital
Johannesburg, South Africa · Recruiting
Hospital Universitario la Paz
Madrid, Spain · Recruiting
Hospital Universitario Virgen del Rocio
Seville, Spain · Recruiting
Sahlgrenska Universitetssjukhuset
Gothenburg, Sweden · Recruiting
Queen Elizabeth Hospital
Birmingham, United Kingdom · Recruiting
St Thomas' Hospital
London, United Kingdom · Recruiting
Great Ormond Street Hospital
London, United Kingdom · Recruiting
Manchester Royal Infirmary
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.